Cyclerion Therapeutics (CYCN) Net Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) posted quarterly Net Margin of 114.97% for Q3 2025, up 93.61% quarter-over-quarter from 1797.85% in Q2 2025.

Cyclerion Therapeutics (CYCN) Net Margin (2019 - 2025) Analysis & Trends

Cyclerion Therapeutics' Net Margin history runs 5 years deep, the most recent figure standing at 114.97% for Q3 2025.

In Q3 2025, Net Margin changed N/A year-over-year to 114.97%; the TTM figure through Sep 2025 stood at 144.83% (changed N/A YoY), while the FY2022 annual figure was 8697.64%, down 553323.0% from the prior year.
Net Margin for Q3 2025 stood at 114.97%, up from 1797.85% in the prior quarter.
The five-year high for Net Margin was 114.97% in Q3 2025, with the low at 23870.97% in Q1 2021.
The 3-year median for Net Margin is 1854.29% (2022), against an average of 4550.26%.
The sharpest annual moves came in 2021 and 2022: Net Margin plunged 2163734 bps in 2021, then jumped 2201668 bps in 2022.
Cyclerion Therapeutics' Net Margin stood at 2950.28% in 2021, then slumped by 51 bps to 4455.23% in 2022, then jumped by 97 bps to 114.97% in 2025.
Business Quant data shows CYCN's Net Margin at 114.97% in Q3 2025, 1797.85% in Q2 2025, and 1798.77% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.47 Bn	131.61 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.36 Bn	78.37 Bn	3.93 Bn	30.23%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	31.16%
4	Moderna	58.99 Bn	53.85 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.74 Bn	28.43 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.01 Bn	9.61 Bn	668.28 Mn	-16.51%
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	12.09%
10	Cyclerion Therapeutics	12.48 Mn	9.24 Mn	-	-

Download Data